Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 47 Prostatic Neoplasms 33 Breast Neoplasms 23 Stomach Neoplasms 16 Squamous Cell Carcinoma of Head and Neck 15 Lung Neoplasms 15 Esophageal Neoplasms 13 Neoplasm Metastasis 11 Sarcoma 9 Neoplasms 9 Colorectal Neoplasms 7 Urinary Bladder Neoplasms 6 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Carcinoma, Transitional Cell 6 Carcinoma, Renal Cell 6 Melanoma 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Small Cell Lung Carcinoma 4 Carcinoma, Ovarian Epithelial 4 Breast Neoplasms, Male 4 Salivary Gland Neoplasms 3 Prostatic Neoplasms, Castration-Resistant 3 Pancreatic Neoplasms 3 Non-Muscle Invasive Bladder Neoplasms 3 Leiomyosarcoma 3 Inflammatory Breast Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Squamous Cell 3

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cancer Related Cognitive Decline × Docetaxel × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡